Vineet Laboratories
VINEETLAB NSE
Vineet Laboratories
HealthcareNSE: VINEETLAB BSE: 543298 Pharmaceuticals & Biotechnology
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹69.01 Cr
Volatility
Moderate
P/E Ratio
63.83
EBITDA
₹8.48 Cr
Return on Equity
-137.85%
Debt to Equity
0.99
Book Value
₹23.75
52W High
₹43.5
52W Low
₹27.96
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
6- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -24.6% over past five years.
- Promoter holding is low: 5.98%
- Company has a low return on equity of -22.7% over last 3 years.
- Promoter holding has decreased over last 3 years: -32.7%
- Working capital days have increased from 26.7 days to 89.0 days
Growth Rate
Revenue Growth
-22.86% higher than
3Y
Net Income Growth
-106% lower than
3Y
Cash Flow Change
274% higher than
3Y
ROE
—
ROCE
-762% lower than
3Y
EBITDA Margin (Avg.)
-177% lower than
3Y
Quarterly Results
| Particulars | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 57.2 | 37.52 | 43.37 | 32.65 | 37.05 | 23.86 | 18.96 | 18.1 | 14.08 | 7.44 | 17.42 | 15.65 | 18.89 |
| Expenses | 51.39 | 37.26 | 39.2 | 33.29 | 33.63 | 24.65 | 19.27 | 22.23 | 25.12 | 7.13 | 14.24 | 13.17 | 16.4 |
| Operating Profit | 5.81 | 0.26 | 4.17 | -0.64 | 3.42 | -0.79 | -0.31 | -4.13 | -11.04 | 0.31 | 3.18 | 2.48 | 2.49 |
| OPM % | 10.16% | 0.69% | 9.61% | -1.96% | 9.23% | -3.31% | -1.64% | -22.82% | -78.41% | 4.17% | 18.25% | 15.85% | 13.18% |
| Other Income | 0.03 | 0.03 | 0.01 | 0.01 | 0.41 | 0.37 | 0.2 | 0.03 | 1.38 | 0.02 | 0.01 | 0.05 | 0.03 |
| Interest | 0.37 | 0.96 | 1.02 | 1.08 | 1.72 | 1.14 | 0.99 | 0.95 | 0.9 | 0.61 | 2.19 | 1.09 | 0.99 |
| Depreciation | 0.62 | 0.61 | 0.61 | 0.63 | 0.67 | 0.61 | 0.62 | 0.62 | 0.66 | 0.63 | 0.63 | 0.63 | 0.54 |
| PBT | 4.85 | -1.28 | 2.55 | -2.34 | 1.44 | -2.17 | -1.72 | -5.67 | -11.22 | -0.91 | 0.37 | 0.81 | 0.99 |
| Tax % | 26.8% | -2.34% | 4.71% | -11.11% | -34.03% | -1.84% | 6.98% | 0.53% | -6.24% | -4.4% | -8.11% | -3.7% | 27.27% |
| Net Profit | 3.55 | -1.25 | 2.42 | -2.07 | 1.92 | -2.13 | -1.83 | -5.71 | -10.53 | -0.87 | 0.4 | 0.85 | 0.73 |
| EPS in Rs | 1.85 | -0.65 | 1.26 | -1.08 | 1 | -1.11 | -0.95 | -2.97 | -5.48 | -0.45 | 0.21 | 0.44 | 0.38 |
Profit & Loss
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 0 | 243 | 191 | 212 | 151 | 75 | 59.4 |
| Expenses | 0.01 | 235 | 178 | 205 | 143 | 91.28 | 50.91 |
| Operating Profit | -0.01 | 8.15 | 13.16 | 7.66 | 7.2 | -16.28 | 8.49 |
| OPM % | — | 3.35% | 6.89% | 3.61% | 4.78% | -21.71% | 14.29% |
| Other Income | 0 | 0.39 | 0.29 | 0.12 | 0.46 | 1.99 | 0.1 |
| Interest | 0 | 2.67 | 2.09 | 3.38 | 4.78 | 3.98 | 4.89 |
| Depreciation | 0 | 1.81 | 2.02 | 2.37 | 2.52 | 2.5 | 2.41 |
| PBT | -0.01 | 4.06 | 9.34 | 2.03 | 0.36 | -20.77 | 1.29 |
| Tax % | 0% | 56.16% | 28.91% | 38.42% | -183.33% | -2.79% | 13.18% |
| Net Profit | -0.01 | 1.78 | 6.64 | 1.25 | 1.03 | -20.19 | 1.11 |
| EPS in Rs | -0.11 | 0.93 | 3.46 | 0.65 | 0.54 | -10.52 | 0.58 |
| Div. Payout % | 0% | 0% | 13.89% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.41 | 9.22 | 9.22 | 9.22 | 9.22 | 9.22 | 19.21 |
| Reserves | -0.01 | 17.4 | 24 | 24.46 | 25.51 | 5.43 | 26.4 |
| Borrowings | 0 | 12.48 | 26.51 | 31.09 | 44.3 | 40.05 | 45.33 |
| Other Liabilities | 0 | 69.64 | 73.59 | 51.08 | 37.84 | 39.84 | 33.84 |
| Total Liabilities | 0.4 | 109 | 133 | 116 | 117 | 94.54 | 125 |
| Fixed Assets | 0 | 19.67 | 21.38 | 26.65 | 26.92 | 25.46 | 24.24 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0.12 | 0.14 | 0.13 | 0.18 | 0.21 | 0.19 |
| Other Assets | 0.4 | 88.95 | 112 | 89.07 | 89.77 | 68.87 | 100 |
| Total Assets | 0.4 | 109 | 133 | 116 | 117 | 94.54 | 125 |
Cash Flow
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating | 0 | 27.49 | 7.63 | -9.62 | -6.61 | 11.49 | -12.03 |
| Investing | 0 | -7.81 | -3.68 | -6.69 | -2.22 | -3.18 | -1.11 |
| Financing | 0 | 18.62 | 11.96 | 0.27 | 8.43 | -8.23 | 29.74 |
| Net Cash Flow | 0 | 38.3 | 15.91 | -16.03 | -0.4 | 0.08 | 16.6 |
| Free Cash Flow | 0 | 27.49 | 7.63 | -17.25 | -9.4 | 10.44 | -13.23 |
| CFO/OP | 0 | 327 | 82 | -87 | -88 | -71 | -144 |
Ratios
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Debtor Days | — | 64.03 | 69.14 | 60.45 | 76.59 | 64.48 | 70.05 |
| Inventory Days | — | 73.12 | 109 | 97.79 | 158 | 260 | 606 |
| Days Payable | — | 114 | 161 | 73.9 | 103 | 175 | 240 |
| Cash Conversion Cycle | — | 23.07 | 17.13 | 84.34 | 131 | 150 | 437 |
| Working Capital Days | — | 14.41 | -19.46 | 20.63 | 28.48 | -37.28 | 88.98 |
| ROCE % | — | 34.08% | 23.13% | 8.69% | 6.65% | -27.95% | 8.49% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Vineet Laboratories insights
29 extracted metrics + investor summaries across FY20–FY25.
Documents
1
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
1d - Submitted Regulation 74(5) certificate for Q4 and FY2026; no demat/remat requests received. 1d - Submitted Regulation 74(5) certificate for Q4 and FY2026; no demat/remat requests received.
2
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
21 Apr - Submitted Regulation 74(5) certificate for Q4 and FY2026; no demat/remat requests received. 21 Apr - Submitted Regulation 74(5) certificate for Q4 and FY2026; no demat/remat requests received.
4
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Feb - Copies of Un-audited standalone financial results of the company for the Third quarter and Nine months ended on December 31, 2025 published in following Newspapers … 16 Feb - Copies of Un-audited standalone financial results of the company for the Third quarter and Nine months ended on December 31, 2025 published in following Newspapers …
5
Board Meeting Outcome for Outcome Of Board Meeting Held On Saturday, February 14, 2026 As Required Under Regulation 30 Of SEBI (LODR) Regulations, 2015
14 Feb - Board approved Q3 and nine-month unaudited results to Dec 31, 2025; limited review unqualified; vendor payments ratified. 14 Feb - Board approved Q3 and nine-month unaudited results to Dec 31, 2025; limited review unqualified; vendor payments ratified.
Frequently Asked Questions about Vineet Laboratories
What does Vineet Laboratories Ltd do?
Incorporated in 2003, Vineet Laboratories Ltd is in designing, developing, manufacturing of API Intermediates and Bulk Drugs
Where is Vineet Laboratories Ltd (VINEETLAB) listed?
Vineet Laboratories Ltd trades as VINEETLAB on the NSE and under code 543298 on the BSE.
Which sector does Vineet Laboratories Ltd belong to?
Vineet Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Vineet Laboratories Ltd?
Vineet Laboratories Ltd has a market capitalisation of ₹69.01 Cr, which places it in the Small Cap band.
What is the PE ratio of Vineet Laboratories Ltd?
Vineet Laboratories Ltd trades at a PE ratio of 63.83, against a book value of ₹23.75 per share.
What is the 52-week high and low of Vineet Laboratories Ltd?
Over the last 52 weeks Vineet Laboratories Ltd has traded between ₹27.96 and ₹43.5.
Does Vineet Laboratories Ltd pay dividends?
Vineet Laboratories Ltd has a dividend yield of 2.79%.
What is the Return on Equity (ROE) of Vineet Laboratories Ltd?
Vineet Laboratories Ltd reported a return on equity of -137.85%. Its debt-to-equity ratio is 0.99.
Company Information
Incorporated in 2003, Vineet Laboratories Ltd is in designing, developing, manufacturing of API Intermediates and Bulk Drugs
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/VINEETLAB.md for Vineet Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.